Skip to main content

Table 2 Virological failure baseline clinical characteristics

From: Virological response to daclatasvir and asunaprevir combination therapy for chronic hepatitis C virus genotype 1b infection in dialysis patients: a prospective, multicenter study

Characteristics Complete (n = 25) Failure (n = 4) P value
Age, years 64.9 ± 8.19 69.5 ± 2.69 0.182
Sex, male (n) [%] 21/25 (80.7) 2/4 (50.0) 0.180
Duration of hemodialysis (years) 16.1 ± 9.5 15.3 ± 10.4 0.393*
Previous treatment (n) [%]
 Naïve 19/25 (76.0) 1/4 (25.0) 0.076
 Relapse and non-viral response 6/25 (24.0) 3/4 (75.0)  
Liver cirrhosis (n) [%] 6/25 (24.0) 3/4 (75.0) 0.076
Serum HCV-RNA levels (log10 IU/mL) 5.06 ± 0.99 5.88 ± 0.28 0.158*
 ≥5.0 log10 IU/mL (n) [%] 16/25 (64.0) 4/4 (100) 0.280
 ≥5.5 log10 IU/mL (n) [%] 9/25 (36) 4/4 (100) 0.030
NS5A inhibitor RAVs (n) [%] 2/25 (8) 0/4 (0) 1.000
  1. Data are expressed as median, number (%), or mean ± standard deviation
  2. *Mann-Whitney U test, Fisher’s exact test